Bharat Parenterals Ltd (BSE: 541096) is a Vadodara, Gujarat-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹1,316 Cr, it ranks #1,452 by market cap among the 6,197 Indian listed companies on FinBizNet, and #44 of 86 in Medicinal Chemicals and Botanical Products. At ₹1,900.00 (as of 16 Nov 2026), the share price is 17.2% below its 52-week high of ₹2,295.10 and 58.2% above its 52-week low of ₹1,201.10. The share price is up 7.6% over one year and up 15.7% over three months.
| Current Price | ₹1,900.00 |
|---|---|
| Market Cap | ₹1,316 Cr |
| BSE Code | 541096 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | Not meaningful (loss) |
| Return on Equity | 4.06% |
| Return on Assets | -1.82% |
| 52-Week Range | ₹1,201.10 – ₹2,295.10 |
| 1-Year Price Change | +7.6% |
| 3-Month Price Change | +15.7% |
| Beta (1Y) | 0.71 |
| Dividend Yield | 0.05% |
| Headquarters | Vadodara, Gujarat |
| Website | bplindia.in |
| Revenue | ₹56 Cr |
|---|---|
| Net Profit | ₹4 Cr |
| Net Margin | 6.6% |
| EPS (Basic) | ₹5.31 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Bharat Parenterals Ltd reported revenue of ₹56 Cr in Q1 FY27, down 41.2% from ₹94 Cr in Q1 FY26 and down 1.8% from ₹57 Cr in Q4 FY26. It posted a net profit of ₹4 Cr for the quarter, against a net profit of ₹10 Cr in Q1 FY26 (down 63.4%). Across the 8 quarters from Q2 FY25 to Q1 FY27, quarterly revenue ranged from ₹41 Cr (Q3 FY26) to ₹94 Cr (Q1 FY26). The company was profitable in each of these 8 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q1 FY27 | ₹56 Cr | ₹4 Cr | 6.6% |
| Q4 FY26 | ₹57 Cr | ₹1 Cr | 2.4% |
| Q3 FY26 | ₹41 Cr | ₹2 Cr | 4.6% |
| Q2 FY26 | ₹42 Cr | ₹3 Cr | 6.5% |
| Q1 FY26 | ₹94 Cr | ₹10 Cr | 10.6% |
| Q4 FY25 | ₹80 Cr | ₹2 Cr | 2.8% |
| Q3 FY25 | ₹67 Cr | ₹7 Cr | 9.7% |
| Q2 FY25 | ₹64 Cr | ₹5 Cr | 8.5% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 51.14% of Bharat Parenterals Ltd's shares as of Mar 2026, unchanged from Mar 2025. Delivery averaged 45.0% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Bharat Parenterals Limited engages in the research, development, manufacturing, marketing, sourcing, and distribution of pharmaceutical products in India and internationally. The company provides antibiotics, cardiovascular and central nervous system, antifungal, antimalarial, gastrointestinal tract/alimentary systems, analgesics, anaesthetics, quinolones, erectile dysfunction medicines, nutritional supplements, steroids and hormones, and other drugs. It also engages in manufacturing of general products in capsules, tablets, ointment and creams, injections, oral liquids, and powder sachets forms; and beta lactum and cephalosporin products in capsules, tablets, dry syrup, and powder for injection forms. In addition, it offers eye drops. Bharat Parenterals Limited was incorporated in 1992 and is based in Vadodara, India.
1. Manufacturing of Pharmaceuticals Formulations-This segment manufactures and sells pharmaceutical formulations. It offers products in the areas of anti retroviral, cephalosporins antibiotics, antiprotozoal/anthelmintic, respiratory, antiallergic/anti histaminic/anticold, cleansing agents/skin infections, antibiotic, cardiovascular systems, anti diabetic, anti tuberculosis, anti-fungal, antimalarial, gastroinestinaltract/alimentary systems, antiinflammatory/anti pyretic/analgesics, supplements, central nervous system, anaesthetics, anti viral, steroids and hormones, uterine stimulant, anticancer, and other.
1. Manufacturing Of Pharma Products-61.1% 2. Trading Of Pharma Products-18% 3. Contract Development And Manufacturing Operations-20.9%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,56,425 Cr | 39.5 | 14.72% | ₹16,199 Cr | +11.2% |
| Laurus Labs Ltd | ₹1,31,242 Cr | 145.6 | 17.74% | ₹2,206 Cr | +146.8% |
| Zydus Lifesciences Ltd | ₹1,19,651 Cr | 24.1 | 18.32% | ₹7,910 Cr | +26.0% |
| Dr.Reddys Lab | ₹1,15,464 Cr | 26.9 | 11.52% | ₹8,698 Cr | +14.5% |
| Cipla Limited | ₹1,14,712 Cr | 29.3 | 11.74% | ₹7,404 Cr | -7.6% |
| Mankind Pharma | ₹1,09,870 Cr | 57 | 12.45% | ₹4,338 Cr | +16.7% |
| Aurobindo Pharma Ltd. | ₹1,05,150 Cr | 30 | 9.93% | ₹10,263 Cr | +59.8% |
| Lupin Ltd | ₹92,087 Cr | 17.3 | 26.91% | ₹7,827 Cr | +0.4% |
| Bharat Parenterals Ltd | ₹1,316 Cr | n/m | 4.06% | ₹56 Cr | +7.6% |
Listed by market capitalisation. Ratios are shown for context only.
Bharat Parenterals Ltd is trading at ₹1,900.00, with a market capitalisation of ₹1,316 Cr.
Bharat Parenterals Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Bharat Parenterals Ltd has a return on equity of 4.06%.
Bharat Parenterals Ltd is listed on the BSE under the scrip code 541096.
Bharat Parenterals Ltd's share price is up 7.6% over one year and up 15.7% over three months. Its 52-week range is ₹1,201.10 to ₹2,295.10.
In Q1 FY27, Bharat Parenterals Ltd reported revenue of ₹56 Cr and net profit of ₹4 Cr, with basic EPS of ₹5.31 (standalone, parsed from the company's exchange filing).
Bharat Parenterals Ltd reported revenue of ₹56 Cr in Q1 FY27, down 41.2% from ₹94 Cr in Q1 FY26 and down 1.8% from ₹57 Cr in Q4 FY26.
Promoters held 51.14% of Bharat Parenterals Ltd's shares as of Mar 2026, unchanged from Mar 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.